Paxlovid(nirmatrelvir, ritonavir)

Mild-to-moderate COVID-19 in high-risk patients 12+.

1 DTP program

From $0 (free)

1 platform

FDA-Approved Indications

Mild-to-moderate COVID-19 in adults at high risk for progression to severe disease

Available direct-to-patient (DTP) programs

Sorted by price, lowest first. Always verify eligibility and pricing directly with the manufacturer.

Lowest price option

via PfizerForAll · Pfizer

$0 (free)

Free via USG PAP through Dec 31, 2026. Commercially insured patients use separate PAXCESS copay program.

Eligibility

Medicare/Medicaid/uninsured = primary eligible population. Income verification added Mar 1, 2025.

Government-insured patients are the primary eligible population for this free program.

Last verified: Mar 2026

Not sure which Paxlovid program fits your situation?